ArticleCancer discovery2021
MNK Inhibition Sensitizes
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 92 citations in OpenAlex.
- RAB1A is a novel vulnerability in uveal melanoma revealed by dual inhibition of MNK1/2 and mTOR.Cell death and differentiation · 2026Article
- Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer.Cell reports · 2026Article
- PFDN5 synergizes with anti-PD1 therapy to promote triple-negative breast cancer cell death through JAK2/STAT3/c-Myc signaling axis.Journal of translational medicine · 2026Article
- KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.Molecular cancer · 2026Review
- Non-gonadal PIWIL1/Aubergine drives regenerative and tumorigenic stem cell proliferation and tumorigenesis in the intestine.Cell reports · 2026Article
- AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs.Nucleic acids research · 2026Article
- Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAFOncology research · 2026Article
- MYC at the tumor-immune interface: mechanisms of immune escape and immunotherapy resistance.Frontiers in immunology · 2026Review
- Nucleophosmin supports WNT-driven hyperproliferation and tumor initiation.Nature genetics · 2026Article
- Mechanisms of mTORC1 and GCN2 amino acid sensing pathways in tumorigenesis and metastatic progression (Review).International journal of molecular medicine · 2026Review
- Tumour Cell Size Control and Its Impact on Tumour Cell Function.Cell proliferation · 2025Review
- YTHDF2 alleviates the radioresistance of rectal cancer cells by targeting methylated MYC.Journal of radiation research · 2025Article
- Rapamycin rescues APC-mutated colon organoid differentiation.Cancer gene therapy · 2025Article
- Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.Nature communications · 2025Article
- PRMT5 Inhibition as a Potential Strategy for KRAS Mutant CRC: Downstream Mediators of the PRMT5-KRAS Crosstalk.Current issues in molecular biology · 2025Article
- TSC2-mutated perivascular epithelioid cell tumor with partial response to mTOR inhibition: a case report and literature review.Discover oncology · 2025Article
- Chemical Probes for Studying the Eukaryotic Translation Initiation Factor 4E (eIF4E)-Regulated Translatome in Cancer.ACS pharmacology & translational science · 2025Review
- Expression of the RPSA-Containing and 67EBP Laminin Receptors in Relation to the Debatable Nature of the 67 kDa Laminin Receptor 67LR in Colorectal Cancer.International journal of molecular sciences · 2025Article
- Translational regulation of SND1 governs endothelial homeostasis during stress.The Journal of clinical investigation · 2025Article
- Targeting protein synthesis pathways in MYC-amplified medulloblastoma.Discover oncology · 2025Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 10 institutions in 4 countries.
John R P KnightCRUK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0002-8771-5484
Constantinos AlexandrouCRUK Beatson Institute, Glasgow, United Kingdom.
George L SkalkaCRUK Beatson Institute, Glasgow, United Kingdom.
Nikola VlahovCRUK Beatson Institute, Glasgow, United Kingdom.
Kathryn PennelInstitute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0003-0186-1331
Leah OfficerMRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.
Ana TeodosioMRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-1386-6730
Georgios KanellosCRUK Beatson Institute, Glasgow, United Kingdom.
David M GayCRUK Beatson Institute, Glasgow, United Kingdom.
Sebastian May-WilsonCRUK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0003-2668-5717
Ewan M SmithCRUK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0003-3690-758X
Arafath K NajumudeenCRUK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0002-3764-5721
Kathryn GilroyCRUK Beatson Institute, Glasgow, United Kingdom.
Rachel A RidgwayCRUK Beatson Institute, Glasgow, United Kingdom.
Dustin J FlanaganCRUK Beatson Institute, Glasgow, United Kingdom.
Rachael C L SmithCRUK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0003-3690-758X
Laura McDonaldDrug Discovery Unit, CRUK Beatson Institute, Glasgow, United Kingdom.
Craig MacKayDrug Discovery Unit, CRUK Beatson Institute, Glasgow, United Kingdom.
Anne CheastyCRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, United Kingdom.ORCID 0000-0001-7868-1027
Kerri McArthurCRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, United Kingdom.
Emma StanwayCRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, United Kingdom.
Joshua D LeachCRUK Beatson Institute, Glasgow, United Kingdom.
Rene JackstadtCRUK Beatson Institute, Glasgow, United Kingdom.
Joseph A WaldronCRUK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0002-5682-5314
Andrew D CampbellCRUK Beatson Institute, Glasgow, United Kingdom.
Georgios VlachogiannisDivision of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-3114-8772
Nicola ValeriDivision of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.
Kevin M HaigisDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-1922-4509
Nahum SonenbergDepartment of Biochemistry and Goodman Cancer Research Center, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-4707-8759
Christopher G ProudLifelong Health, South Australian Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia.
Neil P JonesCRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, United Kingdom.ORCID 0000-0002-7392-3215
Martin E SwarbrickCRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, United Kingdom.ORCID 0000-0001-6942-6067
Heather J McKinnonDrug Discovery Unit, CRUK Beatson Institute, Glasgow, United Kingdom.
William J FallerCRUK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0002-0738-2254
John Le QuesneMRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.
Joanne EdwardsInstitute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-7192-6906
Anne E WillisMRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-1470-8531
Martin BushellCRUK Beatson Institute, Glasgow, United Kingdom.
Owen J SansomCRUK Beatson Institute, Glasgow, United Kingdom. o.sansom@beatson.gla.ac.uk.ORCID 0000-0001-9540-3010
Cancer Research UK Scotland Institute · GBDiscovery Laboratories (United States) · USUniversity of Cambridge · GBUniversity of Glasgow · GBBrigham and Women's Hospital · USInstitute of Cancer Research · GBMcGill University · CARoyal Marsden NHS Foundation Trust · GBSouth Australian Health and Medical Research Institute · AUUniversity of Leicester · GB
Funding
Cancer Research UK 17096Cancer Research UK 21139Cancer Research UK 24388Cancer Research UK 27144Cancer Research UK 29252Cancer Research UK 30062Cancer Research UK A25045European Research Council 311301Medical Research Council MC_EX_G0902052Medical Research Council MC_UP_A600_1023Medical Research Council MC_UP_A600_1024Medical Research Council MC_UU_00025/7Medical Research Council MR/N021800/1Medical Research Council MR/R502327/1Wellcome Trust 201487
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsColorectal NeoplasmsDisease Models, AnimalEukaryotic Initiation Factor-4EHumansIntracellular Signaling Peptides and ProteinsMiceMice, Inbred C57BLMTOR InhibitorsPhosphorylationProtein Serine-Threonine KinasesEukaryotic Initiation Factor-4EIntracellular Signaling Peptides and ProteinsMKNK1 protein, humanMTOR InhibitorsProtein Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.